Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases

Introduction Immunotherapy‐based combinations have become the standard first‐line therapy for metastatic renal cell carcinoma. However, combined immunotherapy for renal collecting duct carcinoma had been reported, but its therapeutic efficacy had been unclear. Case presentation The first case was a...

Full description

Saved in:
Bibliographic Details
Published in:IJU case reports 2022-11, Vol.5 (6), p.438-441
Main Authors: Tamada, Shinji, Ikarashi, Daiki, Tsuyukubo, Takashi, Iwasaki, Kazuhiro, Isurugi, Kazumasa, Ono, Sadahide, Takata, Ryo, Fujisawa, Hiromitsu, Obara, Wataru
Format: Article
Language:English
Subjects:
Antibodies
axitinib
Biopsy
Case Report
Case Reports
Combination therapy
Hypertension
Immunotherapy
Inhibitor drugs
Kidney cancer
Lymphocytes
Medical imaging
Metastasis
Monoclonal antibodies
Patients
pembrolizumab
renal collecting duct carcinoma
Response rates
Stains & staining
Supervision
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Immunotherapy‐based combinations have become the standard first‐line therapy for metastatic renal cell carcinoma. However, combined immunotherapy for renal collecting duct carcinoma had been reported, but its therapeutic efficacy had been unclear. Case presentation The first case was a 62‐year‐old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with multiple bone metastases. After 7 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. The second case was a 71‐year‐old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with lymph node and lung metastases. After 9 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. In both cases, the tumor cell expression of programmed death ligand‐1 was negative, and CD4+ and CD8+ cells were observed in the tumor. Conclusion Combined immunotherapy with pembrolizumab and axitinib may be effective for metastatic renal collecting duct carcinoma.
ISSN:2577-171X
2577-171X
DOI:10.1002/iju5.12504